Biogen Tests Biosimilars Waters In Joint Venture With Samsung
By
Joseph Haas, Daniel Poppy / Email the Authors / “The Pink Sheet” Dec. 12, 2011, Vol. 73, No. 50
Business & Finance / Word Count: 1705 / Article # 00111212009
Executive Summary
A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.